WELCOME TO FIERCE LIFE SCIENCES WEEKLY DIGEST High revenues are one thing, but measures of profit can give a look at the total health of the business—and how efficiently it’s been managed. And while the six largest drugmakers by 2021 revenue all made it into our latest top 10, they did so in a considerably different order when ranked by their bottom lines. Meanwhile some notable names missed out, following acquisitions, restructuring costs and adjustments during the COVID pandemic. Our full list of the most profitable big pharmas, plus our top reads of the week, follow below. | |
|
Featured Story | By Zoey Becker Eli Lilly's Olumiant has snagged the alopecia areata FDA approval its immunology unit has been waiting for. read more |
| |
|---|
|
|  | Webinar: Scale-up Strategies for Late-stage Cell Therapies Thursday, June 23 | 11am ET / 8am PT The number of autologous cell therapy products commercially approved or approaching launch is growing, with allogeneic therapies very close behind. Learn development considerations to help ensure manufacturing processes can support the high throughput needed to support late stage and commercial cell therapies. Register Now. |
|---|
Top Stories Of The Week By James Waldron With the first generation of CAR-T therapies having shaken up the cancer space, all eyes are on what comes next. So it shouldn’t be a surprise that biotechs have already been in touch with Novartis to see whether they can jump onto the Swiss pharma’s T-Charge platform. read more By Angus Liu,Eric Sagonowsky,Kevin Dunleavy,Fraiser Kansteiner,Zoey Becker While revenue reflects how well a pharma company’s products and services are selling, profit represents another important measurement that provides investors a look at the health of the business and how efficiently it has been managed. Here, we rank the top 10 pharma companies by 2021 net income. read more By Gabrielle Masson Day One Biopharmaceuticals appears to be living up to its namesake, unveiling positive initial data for its oral drug tovorafenib, which aims to treat a brain tumor in children that currently has no approved treatment. read more By Eric Sagonowsky Going into a two-day FDA advisory committee meeting this week, bluebird bio faced uncertainty over the viability of its gene therapy prospects. But the drugmaker has impressed an FDA panel and come away with a pair of expert endorsements for its lead drugs. read more By Andrea Park Beta Bionics’ offering is a pocket-sized device that’s equipped with algorithms to automatically dose insulin. Unlike other insulin pumps, however, the iLet system doesn’t require users to set insulin basal rates, glucose correction factors or other insulin regimen parameters, nor do they have to calculate carbohydrates at every meal to determine bolus insulin doses. read more By Angus Liu Pfizer’s Paxlovid has proven useful in COVID-19 patients at high risk of severe disease. But the antiviral drug may not help less vulnerable patients, a clinical trial has shown. read more By Gabrielle Masson Mice on treadmills, the effect of exercise potentially placed in a pill—a new study has both. Researchers studied Lac-Phe, a molecule formed in the blood during exercise, and found it can suppress appetite and reduce obesity in certain mice, as published today in Nature. read more By Nick Paul Taylor GSK’s respiratory syncytial virus (RSV) vaccine has hit the mark in a phase 3 trial in older adults, teeing the company up to file for approval by the end of the year. But the data-devoid statement leaves the big question of how the vaccine will fare in a competitive, blockbuster market unanswered. read more By Angus Liu Alnylam’s closely watched Onpattro follow-on therapy, vutrisiran, has snagged a much-anticipated FDA green light. The approval tees up a possible showdown with Pfizer’s blockbuster Vyndaqel franchise in an increasingly competitive rare disease field. read more By Joseph Keenan Regenxbio has opened the doors at its new $65 million gene therapy manufacturing facility in Rockville, Maryland. read more By Teresa Carey This week on "The Top Line," we discuss our special report on the top 10 most profitable pharma companies in 2021. We also talk about the two bluebird bio gene therapy candidates that won expert recommendations for FDA approvals. Plus, we're back in person (and on billboards) at BIO. read more Resources Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities | 
